Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-08642534 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-08642534 | EXPERIMENTAL | Participants will receive PF-08642534 QD |
| Placebo | EXPERIMENTAL | Participants will receive matching placebo once daily (QD) |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Participants will receive matching placebo QD |
| PF-08642534 | DRUG | Participants will receive PF-08642534 QD |
Inclusion: * Body mass index (BMI) ≥30.0 and ≤40.0 kg/m², and with stable body weight prior to screening. * Participants are generally otherwise healthy but may have mild chronic conditions (eg, dyslipidemia or hypertension) Exclusion: \- Individuals with diabetes, significant cardiovascular, hep...
Top 20 of 35 competitors
PF-08642534 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE) for the treatment of obesity. It is in Phase 1 clinical development and has not been approved by the FDA. It is being studied in a single recruiting trial in the United States.
PF-08642534 is being developed for obesity, a metabolic condition. The only registered trial of PF-08642534 enrolls adults 18 years and older with obesity, and it is not currently approved for any use. Its development is at the Phase 1 stage.
Pfizer, Inc. (ticker PFE) is the developer of PF-08642534. The company is running the Phase 1 program for this small molecule obesity candidate, which is being evaluated in a single recruiting study in the United States.
PF-08642534 is in Phase 1 clinical development. It is an investigational drug and is not FDA approved. One Phase 1 trial is currently recruiting, with no completed trials reported for this asset.
PF-08642534 is being studied in one Phase 1 trial, NCT07731139, titled a study to learn how different amounts of PF-08642534 are tolerated and act in the body of people who have obesity. The trial is recruiting in the United States, is randomized, double blind, and controlled, and plans to enroll 120 participants.